Dossier assessment
Dolutegravir/lamivudine (HIV infection) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Dolutegravir/lamivudine (HIV infection) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Dolutegravir/lamivudine (HIV infection) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults and adolescents with HIV-1 infection whose virus has no known or suspected resistance to integrase inhibitors or lamivudine
Treatment-naive adults: proof of minor added benefit. Treatment-naive adolescents and pretreated adults and adolescents: added benefit not proven.
Additional information
Federal Joint Committee (G-BA)
2020-02-06 A G-BA decision was published.
Project details
- Project no.
- A19-55
- Commission
- Commission awarded on 04.07.2019 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Immune system and infections
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Addendum
Dolutegravir/lamivudine (HIV infection) - Second Addendum to Commission A19-55
Status: Commission completed
-
Addendum
Dolutegravir/lamivudine (HIV infection) - Addendum to Commission A19-55
Status: Commission completed